Review Biology of renal tumour cancer stem cells applied in medicine

Matak, Damian; Szymański, Łukasz; Szczylik, Cezary; Śledziewski, Rafał; Lian, Fei; Bartnik, Ewa; Sobocińska, Anna; Czarnecka, Anna M.

doi:10.5114/wo.2014.47128

Cited by 15 publications

(12 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many of these diseases have a high risk of relapsing within 5 years of surgical resection and this contributes heavily to disease mortality [54]. The cellular source of cancer relapse is currently unknown, although there is strong evidence to suggest that cancer stem cells may be responsible for this relapse in ccRCC and other cancers [55]. Recent work has shown that the production of H 2 S plays a key role in maintaining the stem-like phenotype of cancer cells through induction of stem cell factors OCT4 and NANOG, and through regulation of cellular energy production and oxidative stress [32].…”

Section: Discussionmentioning

confidence: 99%

Inhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential

et al. 2015

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is characterized by Von Hippel–Lindau (VHL)-deficiency, resulting in pseudohypoxic, angiogenic and glycolytic tumours. Hydrogen sulfide (H2S) is an endogenously-produced gasotransmitter that accumulates under hypoxia and has been shown to be pro-angiogenic and cytoprotective in cancer. It was hypothesized that H2S levels are elevated in VHL-deficient ccRCC, contributing to survival, metabolism and angiogenesis. Using the H2S-specific probe MeRhoAz, it was found that H2S levels were higher in VHL-deficient ccRCC cell lines compared to cells with wild-type VHL. Inhibition of H2S-producing enzymes could reduce the proliferation, metabolism and survival of ccRCC cell lines, as determined by live-cell imaging, XTT/ATP assay, and flow cytometry respectively. Using the chorioallantoic membrane angiogenesis model, it was found that systemic inhibition of endogenous H2S production was able to decrease vascularization of VHL-deficient ccRCC xenografts. Endogenous H2S production is an attractive new target in ccRCC due to its involvement in multiple aspects of disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Several molecular markers have been used to identify CSCs and constitute valuable tools for tumor detection and diagnostic, prognostic, and predictive values, as well as determination of therapeutic targets [ 24 ]. Of note, no marker has been found so far that would be expressed only in CSCs [ 25 ].…”

Section: Cancer Stem Cells In Renal Cell Carcinomamentioning

confidence: 99%

Renal Cancer Stem Cells: Characterization and Targeted Therapies

Peired

Sisti

Romagnani

2016

Stem Cells International

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a major neoplasm with high incidence in western countries. Tumors are heterogeneous and are composed of differentiated cancer cells, stromal cells, and cancer stem cells (CSCs). CSCs possess two main properties: self-renewal and proliferation. Additionally, they can generate new tumors once transplanted into immunodeficient mice. Several approaches have been described to identify them, through the expression of cell markers, functional assays, or a combination of both. As CSCs are involved in the resistance mechanisms to radio- and chemotherapies, several new strategies have been proposed to directly target CSCs in RCC. One approach drives CSCs to differentiate into cancer cells sensitive to conventional treatments, while the other proposes to eradicate them selectively. A series of innovative therapies aiming at eliminating CSCs have been designed to treat other types of cancer and have not been experimented with on RCC yet, but they reveal themselves to be promising. In conclusion, CSCs are an important player in carcinogenesis and represent a valid target for therapy in RCC patients.

show abstract

“…A group of targeted agents selective against RCC has been developed and introduced in the clinic over the last decade (4,5). More recently, cancer stem cells (CSCs) or tumor-initiating cells have come into focus as potential treatment targets in solid tumors (6,7) and RCCs (8,9). Sunitinib (SU11248) is a multi-targeted kinase inhibitor of VEGFR-1, -2 and -3, PDGFR-β, mast/stem cell growth factor receptors (SCFR, c-Kit) and FMS-like tyrosine kinase 3 (FLT3) (10).…”

Section: Introductionmentioning

confidence: 99%

Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

This study was designed to analyze the impact of multi-targeted tyrosine kinase inhibitors on the cancer stem cell subpopulation in renal cell cancer. The second objective was to evaluate the effect of tumor growth inhibition related to a tumor niche factor - oxygen deprivation - as hypoxia develops along with the anti-angiogenic activity of tyrosine kinase inhibitors in renal tumors. Cells were treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, in 2D and 3D culture conditions. Cell proliferation along with drug toxicity were evaluated. It was shown that the proliferation rate of cancer stem cells was decreased by the tyrosine kinase inhibitors. The efficacy of the growth inhibition was limited by hypoxic conditions and 3D intratumoral cell-cell interactions. We conclude that understanding the complex molecular interaction feedback loops between differentiated cancer cells, cancer stem cells and the tumor microenvironment in 3D culture should aid the identification of novel treatment targets and to evalute the efficacy of renal cancer therapies. Cell-cell interaction may represent a critical microenvironmental factor regulating cancer stem cell self-renewal potential, enhancing the stem cell phenotype and limiting drug toxicity. At the same time the role of hypoxia in renal cancer stem cell biology is also significant.

show abstract

Review Biology of renal tumour cancer stem cells applied in medicine

Cited by 15 publications

References 64 publications

Inhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential

Inhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential

Renal Cancer Stem Cells: Characterization and Targeted Therapies

Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer

Contact Info

Product

Resources

About